Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German HTA Body Slams Lack Of 'Real Innovation'

Executive Summary

Too many new drugs have the same mechanism of action, says Germany’s health technology appraisal institute, IQWiG.

You may also be interested in...

Industry Demands Rethink Of German HTA Data Requirements

The pharmaceutical industry is calling for more flexible evidence requirements for health technology assessments in Germany after the country’s HTA body, IQWiG, claimed that too many new products entering the market lack additional benefit.

European Commission HTA Proposals Should Mandate Comparative Trials, Says Germany

Pharmaceutical companies should be obliged to carry out comparative trials, according to analysis from Germany’s Institute For Quality and Efficiency in Healthcare, IQWiG.

Countries Urged To Open Up On Managed Entry Deals

Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts